vs

Side-by-side financial comparison of Globavend Holdings Ltd (GVH) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $13.7M, roughly 1.4× Globavend Holdings Ltd). Globavend Holdings Ltd runs the higher net margin — 3.3% vs -177.4%, a 180.7% gap on every dollar of revenue. On growth, Globavend Holdings Ltd posted the faster year-over-year revenue change (63.7% vs -11.5%). Globavend Holdings Ltd produced more free cash flow last quarter ($-1.2M vs $-23.1M).

Globavend Holdings Ltd is a provider of smart unattended retail solutions, focusing on the design, supply, and operation of intelligent vending machines. It primarily serves markets across Australia, New Zealand, and Southeast Asia, offering end-to-end services including hardware manufacturing, inventory management software, and after-sales support to clients in retail, FMCG, and workplace service segments.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

GVH vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.4× larger
LAB
$19.6M
$13.7M
GVH
Growing faster (revenue YoY)
GVH
GVH
+75.1% gap
GVH
63.7%
-11.5%
LAB
Higher net margin
GVH
GVH
180.7% more per $
GVH
3.3%
-177.4%
LAB
More free cash flow
GVH
GVH
$21.9M more FCF
GVH
$-1.2M
$-23.1M
LAB

Income Statement — Q1 FY2025 vs Q3 FY2025

Metric
GVH
GVH
LAB
LAB
Revenue
$13.7M
$19.6M
Net Profit
$450.3K
$-34.7M
Gross Margin
10.5%
48.5%
Operating Margin
5.8%
-168.5%
Net Margin
3.3%
-177.4%
Revenue YoY
63.7%
-11.5%
Net Profit YoY
-49.9%
-28.8%
EPS (diluted)
$6.01
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GVH
GVH
LAB
LAB
Q3 25
$19.6M
Q2 25
$21.8M
Q1 25
$13.7M
$40.8M
Q3 24
$22.1M
Q2 24
$22.5M
Q1 24
$8.4M
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
GVH
GVH
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-33.5M
Q1 25
$450.3K
$-26.0M
Q3 24
$-26.9M
Q2 24
$-45.7M
Q1 24
$898.8K
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
GVH
GVH
LAB
LAB
Q3 25
48.5%
Q2 25
48.8%
Q1 25
10.5%
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
19.8%
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
GVH
GVH
LAB
LAB
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
5.8%
-80.8%
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
13.8%
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
GVH
GVH
LAB
LAB
Q3 25
-177.4%
Q2 25
-153.7%
Q1 25
3.3%
-63.8%
Q3 24
-122.0%
Q2 24
-203.3%
Q1 24
10.7%
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
GVH
GVH
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$6.01
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$12.57
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GVH
GVH
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$915.2K
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.7M
$399.7M
Total Assets
$6.4M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GVH
GVH
LAB
LAB
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$915.2K
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$2.5M
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
GVH
GVH
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
GVH
GVH
LAB
LAB
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$5.7M
$454.6M
Q3 24
$489.3M
Q2 24
$510.3M
Q1 24
$4.4M
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
GVH
GVH
LAB
LAB
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$6.4M
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$6.0M
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
GVH
GVH
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GVH
GVH
LAB
LAB
Operating Cash FlowLast quarter
$-906.3K
$-22.2M
Free Cash FlowOCF − Capex
$-1.2M
$-23.1M
FCF MarginFCF / Revenue
-8.8%
-118.1%
Capex IntensityCapex / Revenue
2.2%
4.5%
Cash ConversionOCF / Net Profit
-2.01×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GVH
GVH
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-906.3K
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-256.6K
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
GVH
GVH
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-1.2M
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-730.0K
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
GVH
GVH
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-8.8%
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-8.7%
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
GVH
GVH
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
2.2%
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
5.6%
1.7%
Q4 23
0.3%
Q3 23
3.6%
Cash Conversion
GVH
GVH
LAB
LAB
Q3 25
Q2 25
Q1 25
-2.01×
Q3 24
Q2 24
Q1 24
-0.29×
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GVH
GVH

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons